
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
AADAT (aminoadipate aminotransferase) encodes a mitochondrial aminotransferase involved in amino acid metabolism. The enzyme catalyzes transamination of alpha-aminoadipic acid, a step in the saccharopine pathway of L-lysine catabolism, and also catalyzes conversion of kynurenine to kynurenic acid, a metabolite with neuroactive properties. Through these activities, AADAT contributes to lysine and tryptophan metabolism and may influence cellular levels of metabolites involved in metabolic and neuronal processes.
A human colon carcinoma cell line developed by Michael Brattain. The cells are derived from colon tissue and are classified as a cancer cell line.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 3
Reference Transcript: NM_001286683
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use






Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?